Pembrolizumab Improves Outcomes in Early-Stage and Locally Advanced or Metastatic Triple-Negative Breast Cancer.

Oncologist · 2022 · PMC8963307 · PMID 35348777

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Pembrolizumab showed a trend toward improved PFS in all groups ( Table 3 ), although the benefit reached statistical significance only in the subgroup of patients with PD-L1 CPS ≥10.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.